Search

Your search keyword '"Sharpe, D."' showing total 884 results
Start Over Author "Sharpe, D."
884 results on '"Sharpe, D."'

20. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up

Author

Chaudhary, M. A., primary, Edmondson-Jones, M., additional, Baio, G., additional, Mackay, E., additional, Penrod, J. R., additional, Sharpe, D. J., additional, Yates, G., additional, Rafiq, S., additional, Johannesen, K., additional, Siddiqui, M. K., additional, Vanderpuye-Orgle, J., additional, and Briggs, A., additional

Published
2022
Full Text
View/download PDF

27. Cost-Effectiveness of Monitoring Patients Post-Stroke With Mobile ECG During the Hospital Stay

Author

Gao, Lan, Moodie, Marj, Freedman, B, Lam, C, Tu, H, Swift, C, Ma, SH, Mok, VCT, Sui, Y, Sharpe, D, Ghia, D, Jannes, J, Davis, S, Liu, X, Yan, B, Gao, Lan, Moodie, Marj, Freedman, B, Lam, C, Tu, H, Swift, C, Ma, SH, Mok, VCT, Sui, Y, Sharpe, D, Ghia, D, Jannes, J, Davis, S, Liu, X, and Yan, B

Abstract

Background The effectiveness of a nurse‐led in‐hospital monitoring protocol with mobile ECG (iECG) was investigated for detecting atrial fibrillation in patients post‐ischemic stroke or post‐transient ischemic attack. The study aimed to assess the cost‐effectiveness of using iECG during the initial hospital stay compared with standard 24‐hour Holter monitoring. Methods and Results A Markov microsimulation model was constructed to simulate the lifetime health outcomes and costs. The rate of atrial fibrillation detection in iECG and Holter monitoring during the in‐hospital phase and characteristics of modeled population (ie, age, sex, CHA2DS2‐VASc) were informed by patient‐level data. Costs related to recurrent stroke, stroke management, medications (new oral anticoagulants), and rehabilitation were included. The cost‐effectiveness analysis outcome was calculated as an incremental cost per quality‐adjusted life‐year gained. As results, monitoring patients with iECG post‐stroke during the index hospitalization was associated with marginally higher costs (A$31 196) and greater benefits (6.70 quality‐adjusted life‐years) compared with 24‐hour Holter surveillance (A$31 095 and 6.66 quality‐adjusted life‐years) over a 20‐year time horizon, with an incremental cost‐effectiveness ratio of $3013/ quality‐adjusted life‐years. Monitoring patients with iECG also contributed to lower recurrence of stroke and stroke‐related deaths (140 recurrent strokes and 20 deaths avoided per 10 000 patients). The probabilistic sensitivity analyses suggested iECG is highly likely to be a cost‐effective intervention (100% probability). Conclusions A nurse‐led iECG monitoring protocol during the acute hospital stay was found to

Published
2022

28. Cost-Effectiveness of Monitoring Patients Post-Stroke With Mobile ECG During the Hospital Stay

Author

Gao, L, Moodie, M, Freedman, B, Lam, C, Tu, H, Swift, C, Ma, S-H, Mok, VCT, Sui, Y, Sharpe, D, Ghia, D, Jannes, J, Davis, S, Liu, X, Yan, B, Gao, L, Moodie, M, Freedman, B, Lam, C, Tu, H, Swift, C, Ma, S-H, Mok, VCT, Sui, Y, Sharpe, D, Ghia, D, Jannes, J, Davis, S, Liu, X, and Yan, B

Abstract

Background The effectiveness of a nurse-led in-hospital monitoring protocol with mobile ECG (iECG) was investigated for detecting atrial fibrillation in patients post-ischemic stroke or post-transient ischemic attack. The study aimed to assess the cost-effectiveness of using iECG during the initial hospital stay compared with standard 24-hour Holter monitoring. Methods and Results A Markov microsimulation model was constructed to simulate the lifetime health outcomes and costs. The rate of atrial fibrillation detection in iECG and Holter monitoring during the in-hospital phase and characteristics of modeled population (ie, age, sex, CHA2DS2-VASc) were informed by patient-level data. Costs related to recurrent stroke, stroke management, medications (new oral anticoagulants), and rehabilitation were included. The cost-effectiveness analysis outcome was calculated as an incremental cost per quality-adjusted life-year gained. As results, monitoring patients with iECG post-stroke during the index hospitalization was associated with marginally higher costs (A$31 196) and greater benefits (6.70 quality-adjusted life-years) compared with 24-hour Holter surveillance (A$31 095 and 6.66 quality-adjusted life-years) over a 20-year time horizon, with an incremental cost-effectiveness ratio of $3013/ quality-adjusted life-years. Monitoring patients with iECG also contributed to lower recurrence of stroke and stroke-related deaths (140 recurrent strokes and 20 deaths avoided per 10 000 patients). The probabilistic sensitivity analyses suggested iECG is highly likely to be a cost-effective intervention (100% probability). Conclusions A nurse-led iECG monitoring protocol during the acute hospital stay was found to improve the rate of atrial fibrillation detection and contributed to slightly increased costs and improved health outcomes. Using iECG to monitor patients post-stroke during initial hospitalization is recommended to complement routine care.

Published
2022

32. Surface dynamics of surfactant solutions

Author

Earnshaw, J. C., McCoo, E., Nugent, C., Sharpe, D. J., Araki, H., editor, Brézin, E., editor, Ehlers, J., editor, Frisch, U., editor, Hepp, K., editor, Jaffe, R. L., editor, Kippenhahn, R., editor, Weidenmüller, H. A., editor, Wess, J., editor, Zittartz, J., editor, Beiglböck, W., editor, and Steinchen, Annie, editor

Published
1996
Full Text
View/download PDF

33. sj-docx-1-mdm-10.1177_0272989X221132257 – Supplemental material for Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up

Author

Chaudhary, M. A., Edmondson-Jones, M., Baio, G., Mackay, E., Penrod, J. R., Sharpe, D. J., Yates, G., Rafiq, S., Johannesen, K., Siddiqui, M. K., Vanderpuye-Orgle, J., and Briggs, A.

Subjects
111708 Health and Community Services, 111799 Public Health and Health Services not elsewhere classified, 160807 Sociological Methodology and Research Methods, FOS: Health sciences, FOS: Sociology
Abstract

Supplemental material, sj-docx-1-mdm-10.1177_0272989X221132257 for Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up by M. A. Chaudhary, M. Edmondson-Jones, G. Baio, E. Mackay, J. R. Penrod, D. J. Sharpe, G. Yates, S. Rafiq, K. Johannesen, M. K. Siddiqui, J. Vanderpuye-Orgle and A. Briggs in Medical Decision Making

Published
2022
Full Text
View/download PDF

35. Variation in paediatric hospital antibiotic guidelines in Europe

Author

Spyridis, N, Syridou, G, Goossens, H, Versporten, A, Kopsidas, J, Kourlaba, G, Bielicki, J, Drapier, N, Zaoutis, T, Tsolia, M, Sharland, M, Vergison, A, Léon, V, Delestrait, M, Huza, C, Lepage, P, Mahieu, L, Boy, T, Jansens, H, Van der Linden, D, Briquet, C, Allegaert, K, Smits, A, Gabriels, P, Vuye, A, Lutsar, I, Tamm, E, Larionova, A, Laan, D, Orbach, M, Lorrot, M, Angoulvant, F, Prot-Labarthe, S, Dubos, F, Lagree, M, Hufnagel, M, Schuster, K, Henneke, P, Roilides, E, Iosifidis, E, Corovessi, V, Michos, A, Galanakis, E, Gkentzi, D, Giacquinto, C, Longo, G, Dona, D, Mion, T, DʼArgenio, P, Degli, ML Ciofi, De Luca, M, Ciliento, G, Esposito, S, Danieli, E, Montinaro, V, Tenconi, R, Nicolini, G, Sviestina, C I Montagnani, Pavare, J, Rasnaca, K, Gardovska, D, Grope, I, Usonis, V, Gurksniene, V, Eidukaite, A, Biver, A, Brett, A, Esteves, I, Cambrea, SC, Craiu, M, Tomescu, E, Cizman, M, Babnik, J, Kenda, R, Vidmar, I, Nunez-Cuadros, E, Rojo, P, Lopez-Varela, E, Ureta, N, Mosqueda, R, Perez-Lopez, A, Orta, L, Santos, M, Navarro, M, Santiago, B, Hernandez-Sampelaya, T, Saavedra, J, Pineiro, R, Torel, P, Mate Cano, I, Baumann, P, Berger, C, Menson, E, Botgros, A, Doerholt, K, Drysdale, S, Makwana, N, McCorry, A, Garbash, EM, Chetcutiganado, C, McLeod, M, Caldwell, N, Nash, C, McCullagh, B, Sharpe, D, Tweddell, L, Liese, JG, Aston, J, Gallagher, A, Satodia, P, Howard-Smith, N, Korinteli, I, Tavchioska, G, Jensen, L, Trethon, A, Unuk, S, Childs, N, and Canlas, J

Published
2016
Full Text
View/download PDF

41. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.

Author

Chaudhary, M. A., Edmondson-Jones, M., Baio, G., Mackay, E., Penrod, J. R., Sharpe, D. J., Yates, G., Rafiq, S., Johannesen, K., Siddiqui, M. K., Vanderpuye-Orgle, J., and Briggs, A.

Abstract

Objectives: Immuno-oncology (IO) therapies are often associated with delayed responses that are deep and durable, manifesting as long-term survival benefits in patients with metastatic cancer. Complex hazard functions arising from IO treatments may limit the accuracy of extrapolations from standard parametric models (SPMs). We evaluated the ability of flexible parametric models (FPMs) to improve survival extrapolations using data from 2 trials involving patients with non–small-cell lung cancer (NSCLC). Methods: Our analyses used consecutive database locks (DBLs) at 2-, 3-, and 5-y minimum follow-up from trials evaluating nivolumab versus docetaxel in patients with pretreated metastatic squamous (CheckMate-017) and nonsquamous (CheckMate-057) NSCLC. For each DBL, SPMs, as well as 3 FPMs—landmark response models (LRMs), mixture cure models (MCMs), and Bayesian multiparameter evidence synthesis (B-MPES)—were estimated on nivolumab overall survival (OS). The performance of each parametric model was assessed by comparing milestone restricted mean survival times (RMSTs) and survival probabilities with results obtained from externally validated SPMs. Results: For the 2- and 3-y DBLs of both trials, all models tended to underestimate 5-y OS. Predictions from nonvalidated SPMs fitted to the 2-y DBLs were highly unreliable, whereas extrapolations from FPMs were much more consistent between models fitted to successive DBLs. For CheckMate-017, in which an apparent survival plateau emerges in the 3-y DBL, MCMs fitted to this DBL estimated 5-y OS most accurately (11.6% v. 12.3% observed), and long-term predictions were similar to those from the 5-y validated SPM (20-y RMST: 30.2 v. 30.5 mo). For CheckMate-057, where there is no clear evidence of a survival plateau in the early DBLs, only B-MPES was able to accurately predict 5-y OS (14.1% v. 14.0% observed [3-y DBL]). Conclusions: We demonstrate that the use of FPMs for modeling OS in NSCLC patients from early follow-up data can yield accurate estimates for RMST observed with longer follow-up and provide similar long-term extrapolations to externally validated SPMs based on later data cuts. B-MPES generated reasonable predictions even when fitted to the 2-y DBLs of the studies, whereas MCMs were more reliant on longer-term data to estimate a plateau and therefore performed better from 3 y. Generally, LRM extrapolations were less reliable than those from alternative FPMs and validated SPMs but remained superior to nonvalidated SPMs. Our work demonstrates the potential benefits of using advanced parametric models that incorporate external data sources, such as B-MPES and MCMs, to allow for accurate evaluation of treatment clinical and cost-effectiveness from trial data with limited follow-up. Highlights: Flexible advanced parametric modeling methods can provide improved survival extrapolations for immuno-oncology cost-effectiveness in health technology assessments from early clinical trial data that better anticipate extended follow-up. Advantages include leveraging additional observable trial data, the systematic integration of external data, and more detailed modeling of underlying processes. Bayesian multiparameter evidence synthesis performed particularly well, with well-matched external data. Mixture cure models also performed well but may require relatively longer follow-up to identify an emergent plateau, depending on the specific setting. Landmark response models offered marginal benefits in this scenario and may require greater numbers in each response group and/or increased follow-up to support improved extrapolation within each subgroup. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results